Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04447118
Title Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Jiangsu HengRui Medicine Co., Ltd.
Indications

lung non-squamous non-small cell carcinoma

Therapies

Pyrotinib

Docetaxel

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.